Event Brief
Neurocrine invests $3bn in hunger treatment deal
Filed: Apr 06, 2026 at 12:09 PM ET
Summary: Neurocrine Biosciences acquires Soleno Therapeutics' drug for Prader-Willi syndrome.
WHO: Neurocrine Biosciences
WHAT: acquires Soleno Therapeutics' drug
WHEN: Apr 06, 2026 at 8:04 AM ET
WHERE: USA
WHY: To address extreme hunger caused by Prader-Willi syndrome.
ℹ️ This event is analyzed using pattern arcs, velocity indicators, and source analysis in our MI Console.
Know more. Read less.
The BriefBrief follows the story, so you don't have to read every article. See what happened, how it changed, and where it came from, all in one place.
Same format. Every time.
See how stories unfold →